An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Completed · Phase 1

Conditions studied: Triple Negative Breast Cancer, Metastatic Breast Cancer

In brief

Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer

Key facts

Study ID

NCT03243331

Run by

Kathy Miller

People needed

18

Starts

2018-01-19

Expected to finish

2020-05-27

Last updated by the study team

2021-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic Triple-negative Breast Cancer
• Willingness to undergo tumor biopsy
• Patients must have received at least 1 prior chemotherapy regimen for metastatic disease

You may not qualify if…

• Previous treatment with mTOR inhibitor
• Untreated brain metastases

Where it is running

• IU Simon Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.